Hepatitis C screening, diagnostic testing, and monitoring
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage criteria for Hepatitis C virus (HCV) screening, diagnostic (antibody and RNA) testing, genotype testing, and monitoring in affected individuals; applicable to Blue Cross Blue Shield - Tennessee members and providers administering HCV-related testing and follow-up care.
No material clinical or coverage changes in this revision.
Coverage Criteria for HCV Testing and Monitoring
inv-01: Covered indications for HCV testing and monitoring
Covered when any of the following criteria are met:
Ref: Avalon Policy AHS-G2035-Prenatal Screening
List of recognized exposures included
Additional exposures listed in policy
Follow CDC recommendations for repeat testing
Genotype influences regimen selection
Used to differentiate clearance from persistence
Supports assessment of virologic response and sustained virologic response (SVR)
inv-02: Testing and monitoring
Covered/testing recommended per cited society guidance when applicable to patient care:
Supported by CASL and AGA guidance
Conflicting guidance between societies
AGA recommendations
CASL suggests annual RNA testing for reinfection risk; AGA recommends periodic testing for ongoing risk factors
IHS, CDC and other guidance referenced
A hepatitis C vaccine is not available; therefore, vaccination is not a covered prevention option. The source explains that multiple candidate vaccines are under development but none are currently available, and cites scientific and practical barriers to vaccine development.
The Canadian Task Force on Preventive Health Care (CTFPHC) recommends against screening adults who are not at elevated risk for HCV (strong recommendation, very low-quality evidence). This recommendation should be considered when applying routine population screening decisions.
No explicit exclusions were identified in the cited bibliographic and reference materials included in this policy section. The listed references and guideline documents serve as supporting literature rather than providing discrete exclusion criteria.
EASL guidance states that testing for HCV resistance prior to treatment is not recommended when such testing would limit access to care. EASL notes genotype/subtype determination remains useful where available and does not impede access, but resistance testing should not be required if it would create barriers.
Among the referenced guideline and bibliographic listings in this section, no conditions were specified as universally not medically necessary; the documents primarily provide clinical guidance and supporting evidence rather than explicit noncoverage statements.
Provider Actions, Documentation, and Billing Notes
Prior authorization / benefit-dependent coverage
Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request; coverage of HCV testing is therefore subject to the member's benefit plan terms and any Medicare/Medicaid specifications referenced in Section VII.
LDT regulatory requirements (CLIA high-complexity)
Laboratory-developed tests (LDTs) used for HCV testing are regulated by CMS as high-complexity tests under CLIA '88; FDA clearance or approval is not required for clinical use, though payers may require documentation of test validation.
No prior authorization specified in references
The bibliographic citations and extracted sections do not specify any prior authorization requirements for HCV testing beyond benefit-plan dependence.
Step therapy not specified for testing
No step therapy requirements for HCV testing or monitoring are specified in the extracted testing and monitoring sections; treatment selection is informed by genotype testing prior to therapy.
Step therapy (none specified)
Step therapy is not specified in the society guidance and reference sections included in this policy.
References do not describe step therapy
No step therapy requirements are described in the listed reference materials for HCV testing or monitoring.
Document indication and test results
Document the clinical indication for testing (e.g., screening, recognized exposure, ongoing risk, abnormal ALT, or pregnancy per prenatal screening policy) and record the results of antibody and confirmatory NAT/NAAT testing when performed.
- Indication: screening, exposure, ongoing risk, abnormal ALT, or pregnancy (see prenatal screening policy)
- Results: antibody assay result and confirmatory quantitative NAT/NAAT result
Document baseline HCV RNA, genotype, and hepatic panel
Prior to initiating antiviral therapy, document quantitative HCV RNA and genotype (and subtype when available) and baseline hepatic function panel including albumin, total/direct bilirubin, ALT, AST, and alkaline phosphatase (and consider CBC and INR as recommended).
- HCV RNA (quantitative) and genotype (one-time pre-treatment)
- Baseline hepatic panel: albumin, total/direct bilirubin, ALT, AST, alkaline phosphatase; consider CBC and INR
References: no additional documentation requirements
The bibliographic references cited provide supporting literature but do not add additional, specific documentation requirements beyond those listed in the policy.
Benefit eligibility may affect coverage
Coverage determinations depend on the member's benefit eligibility at the time of request; services that fall outside a member's specific benefit specifications (including Medicare Part B/Part D or state Medicaid distinctions) may not be covered.
Government policies supersede this policy when conflicting
If this policy conflicts with an applicable government policy (e.g., Medicare LCDs/NCDs or state Medicaid rules), the government policy governs and determinations will follow that policy.
No specific denial triggers listed
No explicit denial triggers are specified within the referenced bibliographic listings for HCV testing and monitoring in these chunks.
Background on Hepatitis C
Hepatitis C virus (HCV) is a blood-borne RNA virus that causes liver inflammation and can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Many infections are asymptomatic, so screening and diagnostic testing (initial anti-HCV antibody followed by confirmatory HCV RNA NAT/NAAT) are important to identify active infection and link patients to curative antiviral therapy. Genotype and baseline hepatic function assessment guide regimen selection and treatment monitoring.
Definitions and Abbreviations
Guidelines, References, and Supporting Evidence
This policy references multiple international and national guideline sources and bibliographic resources to support testing and monitoring recommendations, including USPSTF, WHO, World Gastroenterology Organization (WGO), Canadian Association for the Study of the Liver (CASL), American Gastroenterological Association (AGA), European Association for the Study of the Liver (EASL), and Indian Health Services (IHS). These documents provide the evidence base for coverage criteria such as one-time adult screening, targeted or risk-based screening, diagnostic testing algorithms, pre-treatment assessment, and follow-up to confirm sustained virologic response.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.